Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients
Authors: Bader Peter , Kuci Selim , Kuci Zyrafete , Bakhtiar Shahrzad , Basu Oliver , Bug Gesine , Dennis Michael , Greil Johann , Barta Aniko , Kallay Krisztián , Lang Peter , Lucchini Giovanna , Pol Raj , Schulz Ansgar , Sykora Karl-Walter , Teichert von Luettichau Irene , Herter-Sprie Grit , Uddin Mohammad Ashab , Jenkin Philip , Alsultan Abdulrahman , Büchner Jochen , Stein Jerry , Kelemen Agnes , Jarisch Andrea , Soerensen Jan , Salzmann-Manrique Emilia , Hutter Martin , Schaefer Richard , Seifried Erhard , Paneesha Shankara , Novitzky-Basso Igor , Gefen Aharon , Nevo Neta , Beutel Gernot , Schlegel Paul G. , Klingebiel Thomas , Bonig Halvard 
Published: October 2019

Introduction: Since the seminal paper of LeBlanc in 2008, despite several negative studies, the scientific community has retained optimism with respect to the usefulness of mesenchymal stroma cells (MSCs) in refractory acute graft-versus-host disease (GvHD). A prevailing theme of past studies was that, while pediatric GvHD responded to MSCs, adult GvHD did not. As reported, we developed proprietary protocols GMP-quality MSC production from bone marrow (BM) mononuclear cells expanded in platelet lysate-enriched media.

Patients and Methods: We present treatment data with MSC-FFM for 61 children/adolescents and 31 adults with either "only" steroid-refractory (SR) GvHD (27%) or GvHD which had additionally proven refractory to up to five additional lines of therapy (MR-GvHD) (73%). Pediatric patients tended to have more MR-GvHD than adults. Patients from 23 centers in 6 countries were included. Most patients had severe GvHD (37% °III, 59% °IV, Glucksberg scale). 31 patients (34%) were female,61 male (66%). 69 have a malignant disease (75%), and 23 a non-malignant (25%) disease as indication for transplantation. Donors were MSD (n=21, 23%), MUD (n=56, 61%), haploidentical (n=14, 15%), and 1 MMUD (1%).

Patients received myeloablative conditioning with TBI-, Treosulfan-, Busulfan- and Fludarabine-based regimen, with serotherapy, mostly ATG. 89% of patients had had immunosuppression for GvHD prophylaxis, 13% CSA alone, 49% CSA+MTX or MMF; or others (n=15, 16%). Median onset of aGvHD was at 40 days (range: 6-280 d), another 28 days (range: 5-380) until the first infusion of MSC-FFM. Recommended dose and interval is 4 weekly doses of 1-2M MSC/kg body weight; the average patient received only 3 doses, the interval approximately staggered as recommended, with a median dose of 1.4M MSC/kg. Any reduction in GvHD activity by at least one full grade was classified as a partial (PR), absence of any degree of GvHD as a complete response (CR).

Results: Day-28 response rates were 84%/25%/59% overall (OR)/CR/PR for children and 80%/35%/45% for adults resulting in a day-28 response rate for the entire cohort: 82%/28%/54%). At last follow-up (LFU) many of the pediatric responders had continued to improve from partial to complete response to response rates of 84%/59%/25% OR/CR/PR, in adults responses were largely unchanged (77%/35%/42%; LFU for the entire cohort: 81%/51%/30%). GvHD °III and °IV were equally likely to respond or resolve. Looking at response rates of SR- vs. MR-GvHD, of the SR-GvHD 96% responded (MR-GvHD: 81%), as well as early and LFU responses in SR-GvHD were more likely to be complete responses (60% and 72% for SR-GvHD, 16% and 43% for MR-GvHD, day-28 and LFU, respectively).

Day-28-response was highly predictive of long-term responsiveness, in that only one non-responder on day 28 achieved a response long term, and only two initial partial responders' GvHD relapsed to the same degree of severity as before MSC treatment.

The historical expected survival probability for patients with steroid-refractory severe GvHD being in the order of 20% at 6 months. The patients reported here with °III or °IV aGVHD achieved 6-month overall survival probabilities of 65% and 61%, respectively. In total 6 patients relapsed and died (of note: only 69 patients were at risk), 28 deaths were treatment-related. 6-month overall survival rates for children and adults were 68% and 54%, respectively (n.s.). In terms of adverse reactions to MSC-FFM, one case each of spontaneously remitting headache and nausea/vomiting were reported shortly after infusion of the thawed cells. Both events occurred in children and were possibly related to the rapid infusion of DMSO-containing ice-cold fluid and not the active substance.

Conclusion: MSC-FFM emanates as a highly efficacious treatment for severe pediatric and adult advanced GvHD, with OR in excess of 80% and survival rates approximating those of patients without GvHD. The very low relapse mortality may suggest that severe GvHD effectively suppresses leukemic recurrence. Better and faster responses of SR- vs. MR-GvHD make a case for early treatment with MSC-FFM.

Disclosures

Bader: Medac: Patents & Royalties, Research Funding; Cellgene: Consultancy; Neovii: Research Funding; Riemser: Research Funding; Novartis: Consultancy, Speakers Bureau. Kuci:Medac: Patents & Royalties. Kuci:Medac: Patents & Royalties. Bug:Amgen: Honoraria; Jazz Pharmaceuticals: Other: Travel Grant; Neovii: Other: Travel Grant; Astellas Pharma: Other: Travel Grant; Janssen: Other: Travel Grant; Celgene: Honoraria; Novartis Pharma: Honoraria, Research Funding. Lang:Miltenyi Biotec: Patents & Royalties, Research Funding. Sykora:Aventis-Behring: Research Funding; medac: Research Funding. Seifried:Medac: Other: BSD owns IP and is contract manufacturer; Uniqure BV: Research Funding. Bonig:Kiadis Pharma: Consultancy.